Literature DB >> 20400974

Inflammatory bowel disease and intestinal cancer: a paradigm of the Yin-Yang interplay between inflammation and cancer.

S Danese1, A Mantovani.   

Abstract

Colon cancer represents a paradigm for the connection between inflammation and cancer in terms of epidemiology and mechanistic studies in preclinical models. Key components of cancer promoting inflammation include master transcription factors (for example, nuclear factor kappaB, STAT3), proinflammatory cytokines (for example, tumor necrosis factor, interleukin-6 (IL-6)), cyclooxygenase-2 and selected chemokines (for example, CCL2). Of no less importance are mediators that keep inflammation in check, including IL-10, transforming growth factorbeta, toll-like receptor and the IL-1 receptor inhibitor TIR8/SIGIRR, and the chemokine decoy and scavenger receptor D6. Dissection of molecular pathways involved in colitis-associated cancer may offer opportunities for innovative therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20400974     DOI: 10.1038/onc.2010.109

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  78 in total

1.  Apolipoprotein A-I inhibits experimental colitis and colitis-propelled carcinogenesis.

Authors:  K K Gkouskou; M Ioannou; G A Pavlopoulos; K Georgila; A Siganou; G Nikolaidis; D C Kanellis; S Moore; K A Papadakis; D Kardassis; I Iliopoulos; F A McDyer; E Drakos; A G Eliopoulos
Journal:  Oncogene       Date:  2015-08-17       Impact factor: 9.867

2.  Loss of JNK2 increases intestinal tumor susceptibility in Apc1638+/- mice with dietary modulation.

Authors:  Xiuli Bi; Nicole M Pohl; Zhinan Yin; Wancai Yang
Journal:  Carcinogenesis       Date:  2010-12-23       Impact factor: 4.944

3.  Heparanase powers a chronic inflammatory circuit that promotes colitis-associated tumorigenesis in mice.

Authors:  Immanuel Lerner; Esther Hermano; Eyal Zcharia; Dina Rodkin; Raanan Bulvik; Victoria Doviner; Ariel M Rubinstein; Rivka Ishai-Michaeli; Ruth Atzmon; Yoav Sherman; Amichay Meirovitz; Tamar Peretz; Israel Vlodavsky; Michael Elkin
Journal:  J Clin Invest       Date:  2011-04-01       Impact factor: 14.808

4.  Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer.

Authors:  Jessica E S Shay; Hongxia Z Imtiyaz; Sharanya Sivanand; Amy C Durham; Nicolas Skuli; Sarah Hsu; Vera Mucaj; T S Karin Eisinger-Mathason; Bryan L Krock; Dionysios N Giannoukos; M Celeste Simon
Journal:  Carcinogenesis       Date:  2014-01-09       Impact factor: 4.944

5.  Autoimmunity and Cancer, the Paradox Comorbidities Challenging Therapy in the Context of Preexisting Autoimmunity.

Authors:  Julio C Valencia; Nkolika Egbukichi; Rebecca A Erwin-Cohen
Journal:  J Interferon Cytokine Res       Date:  2018-12-18       Impact factor: 2.607

Review 6.  Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk?

Authors:  Jessica K Dyson; Matthew D Rutter
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

7.  S100A8/A9 activate key genes and pathways in colon tumor progression.

Authors:  Mie Ichikawa; Roy Williams; Ling Wang; Thomas Vogl; Geetha Srikrishna
Journal:  Mol Cancer Res       Date:  2011-01-12       Impact factor: 5.852

Review 8.  Role of autophagy in cancer prevention.

Authors:  Hsin-Yi Chen; Eileen White
Journal:  Cancer Prev Res (Phila)       Date:  2011-07

9.  AOM/DSS Model of Colitis-Associated Cancer.

Authors:  Bobak Parang; Caitlyn W Barrett; Christopher S Williams
Journal:  Methods Mol Biol       Date:  2016

10.  Intestinal inflammation targets cancer-inducing activity of the microbiota.

Authors:  Janelle C Arthur; Ernesto Perez-Chanona; Marcus Mühlbauer; Sarah Tomkovich; Joshua M Uronis; Ting-Jia Fan; Barry J Campbell; Turki Abujamel; Belgin Dogan; Arlin B Rogers; Jonathan M Rhodes; Alain Stintzi; Kenneth W Simpson; Jonathan J Hansen; Temitope O Keku; Anthony A Fodor; Christian Jobin
Journal:  Science       Date:  2012-08-16       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.